Use of Al18F-PSMA-BCH PET/CT Imaging to Detect Prostate Specific Membrane Antigen Positive Tumors Including Prostate and Other Cancers

What this Trial Is About

This research aims to evaluate the tumor detection ability of Al18F-PSMA-BCH PET/CT imaging in patients who have tumors expressing prostate specific membrane antigen (PSMA). These tumors include prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, and others. The study is a Phase 2 clinical trial focused on assessing the effectiveness of this imaging technique in detecting these specific tumors. Participants will receive an intravenous injection of the Al18F-PSMA-BCH tracer followed by a PET/CT scan to visualize PSMA positive tumors. This imaging procedure is used to detect and evaluate the presence of tumors expressing PSMA. The study involves only this intervention without comparison groups, focusing on the diagnostic performance of Al18F-PSMA-BCH PET/CT. During the study, participants will undergo the PET/CT scan after tracer injection. Researchers will monitor the diagnostic value of the imaging throughout the study period, which averages about 1 year. Participants must cooperate with all study procedures and provide informed consent. Safety and diagnostic results will be observed and evaluated to determine how well the imaging detects PSMA positive tumors.

Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor